Jérôme R Lechien1,2,3, Robin Baudouin4, Marta P Circiu4, Carlos M Chiesa-Estomba5, Lise Crevier-Buchman4,6, Stephane Hans4,6. 1. Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Jerome.Lechien@umons.ac.be. 2. Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Jerome.Lechien@umons.ac.be. 3. Department of Otolaryngology, Elsan Hospital, Paris, France. Jerome.Lechien@umons.ac.be. 4. Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. 5. Department of Otorhinolaryngology and Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain. 6. Phonetics and Phonology Lab, CNRS UMR7018, Univ. Sorbonne University, Paris, France.
Abstract
OBJECTIVE: The objective of this study was to investigate feasibility, surgical, oncological, and functional outcomes of transoral robotic cordectomy (TORS-Co) and whether TORS-Co reported comparable outcomes of transoral laser microsurgery (TLM). METHODS: PubMed, Scopus, and Cochrane Library were searched by three laryngologists for studies investigating feasibility, surgical, oncological, and functional outcomes of patients benefiting from TORS-Co. The following outcomes were investigated according to the PRISMA statements: age; cT stage; types of cordectomy; surgical settings; complications; and functional and feasibility features. RESULTS: Nine studies published between 2009 and 2021 met our inclusion criteria, accounting for 114 patients. There was no controlled study. TORS-Co was performed in cT1 or cT2 glottic cancer through types II, III, IV, V, or VI cordectomies. The exposure was inadequate in 4% of cases, leading to conversion in transoral laser cordectomy. Margins were positive in 4.5% and local recurrence occurred in 10.7% (N = 8/75). Tracheotomy and feeding tube requirement varied across studies, depending on the types of TORS-Co. The mean duration of robot installation/vocal cord exposure and operative times ranged from 20 to 42 min and 10 to 40 min, respectively. The mean duration of hospital stay ranged from 2 to 7 days. Complications included dyspnea, bleeding, granuloma, synechia, and tongue hematoma and dysesthesia. CONCLUSION: The current robotic systems do not appear adequate for TORS-Co. TORS-Co was associated with higher rates of complications and tracheotomy than TLM.
OBJECTIVE: The objective of this study was to investigate feasibility, surgical, oncological, and functional outcomes of transoral robotic cordectomy (TORS-Co) and whether TORS-Co reported comparable outcomes of transoral laser microsurgery (TLM). METHODS: PubMed, Scopus, and Cochrane Library were searched by three laryngologists for studies investigating feasibility, surgical, oncological, and functional outcomes of patients benefiting from TORS-Co. The following outcomes were investigated according to the PRISMA statements: age; cT stage; types of cordectomy; surgical settings; complications; and functional and feasibility features. RESULTS: Nine studies published between 2009 and 2021 met our inclusion criteria, accounting for 114 patients. There was no controlled study. TORS-Co was performed in cT1 or cT2 glottic cancer through types II, III, IV, V, or VI cordectomies. The exposure was inadequate in 4% of cases, leading to conversion in transoral laser cordectomy. Margins were positive in 4.5% and local recurrence occurred in 10.7% (N = 8/75). Tracheotomy and feeding tube requirement varied across studies, depending on the types of TORS-Co. The mean duration of robot installation/vocal cord exposure and operative times ranged from 20 to 42 min and 10 to 40 min, respectively. The mean duration of hospital stay ranged from 2 to 7 days. Complications included dyspnea, bleeding, granuloma, synechia, and tongue hematoma and dysesthesia. CONCLUSION: The current robotic systems do not appear adequate for TORS-Co. TORS-Co was associated with higher rates of complications and tracheotomy than TLM.
Authors: Ray Gervacio F Blanco; Patrick K Ha; Joseph A Califano; John M Saunders Journal: J Laparoendosc Adv Surg Tech A Date: 2011-02-16 Impact factor: 1.878
Authors: Matthew D F McInnes; David Moher; Brett D Thombs; Trevor A McGrath; Patrick M Bossuyt; Tammy Clifford; Jérémie F Cohen; Jonathan J Deeks; Constantine Gatsonis; Lotty Hooft; Harriet A Hunt; Christopher J Hyde; Daniël A Korevaar; Mariska M G Leeflang; Petra Macaskill; Johannes B Reitsma; Rachel Rodin; Anne W S Rutjes; Jean-Paul Salameh; Adrienne Stevens; Yemisi Takwoingi; Marcello Tonelli; Laura Weeks; Penny Whiting; Brian H Willis Journal: JAMA Date: 2018-01-23 Impact factor: 56.272
Authors: Luigi Angelo Vaira; Andrea De Vito; Jerome R Lechien; Carlos Miguel Chiesa-Estomba; Miguel Mayo-Yàñez; Christian Calvo-Henrìquez; Paolo Boscolo-Rizzo; Claire Hopkins; Giacomo De Riu Journal: Laryngoscope Date: 2021-12-15 Impact factor: 3.325
Authors: Young Min Park; Woo Jung Lee; Jeong Gwon Lee; Won Sang Lee; Eun Chang Choi; Sa Myung Chung; Se-Heon Kim Journal: J Laparoendosc Adv Surg Tech A Date: 2009-06 Impact factor: 1.878
Authors: Elisabeth V Sjögren; Maya A van Rossum; Ton P M Langeveld; Marika S Voerman; Vivienne A H van de Kamp; Robert J Baatenburg de Jong Journal: Head Neck Date: 2009-11 Impact factor: 3.147
Authors: Stéphane Hans; Robin Baudouin; Marta P Circiu; Florent Couineau; Quentin Lisan; Lise Crevier-Buchman; Jerome R Lechien Journal: J Clin Med Date: 2022-09-29 Impact factor: 4.964